ANAPTYSBIO, INC: Sirenia Capital Management LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Sirenia Capital Management LP amended its Schedule 13G filing on AnaptysBio, Inc. with the SEC under accession number 0000919574-26-007951. The amendment updates the investment firm's previously reported beneficial ownership position in the clinical-stage biotechnology company. Schedule 13G filings are required of investors holding passive stakes above 5% of a class of registered equity securities. The revised disclosure signals a change in Sirenia's holdings, though the filing summary did not specify the exact share count or percentage. Investors will watch for the full filing details to gauge the size and direction of the stake adjustment.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
AnaptysBio, Inc., Sirenia Capital Management LP